Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity-Reference-Cited by-同舟云学术

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

Published:2016-07-14 Issue:2 Volume:128 Page:195-203
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Lampson Benjamin L.¹^ORCID,Kasar Siddha N.¹,Matos Tiago R.¹,Morgan Elizabeth A.²^ORCID,Rassenti Laura³⁴,Davids Matthew S.¹⁴,Fisher David C.¹,Freedman Arnold S.¹,Jacobson Caron A.¹,Armand Philippe¹,Abramson Jeremy S.⁵,Arnason Jon E.⁶,Kipps Thomas J.³⁴,Fein Joshua¹^ORCID,Fernandes Stacey¹⁴,Hanna John¹,Ritz Jerome¹^ORCID,Kim Haesook T.⁷^ORCID,Brown Jennifer R.¹⁴

Affiliation:

1. Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;

2. Department of Pathology, Brigham and Women's Hospital, Boston, MA;

3. Division of Hematology/Oncology, Department of Medicine, University of California, San Diego, La Jolla, CA;

4. CLL Research Consortium, Moores UCSD Cancer Center, La Jolla, CA;

5. Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA;

6. Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA; and

7. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA

Abstract

Key Points Idelalisib as upfront therapy for CLL caused an early hepatotoxicity in a subset of primarily younger patients with IGHV-mutated disease. Multiple lines of evidence suggest that this adverse effect is immune mediated, perhaps through inhibition of regulatory T cells.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/2/195/1397296/195.pdf

Reference37 articles.

1. Second interim analysis of a phase 3 study of idelalisib (ZYDELIG®) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): Efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors [abstract].;Sharman;Blood,2014

2. Update on a phase 1 study of the selective PI3K-delta inhibitor, idelalisib (GS-1101) in combination with ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia.;Coutre;Haematologica,2013

3. A phase 1 study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with therapeutic anti-CD20 antibodies (rituximab or ofatumumab) in patients with relapsed or refractory chronic lymphocytic leukemia [abstract].;De Vos;Blood,2013

Cited by 254 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects;European Journal of Medicinal Chemistry;2024-02

2. Small molecule inhibitors targeting regulatory T cells for cancer treatment;European Journal of Immunology;2023-11-15

3. Exploring and exploiting the host cell autophagy during Mycobacterium tuberculosis infection;European Journal of Clinical Microbiology & Infectious Diseases;2023-09-23

4. Liver Pathology Related to Onco-Therapeutic Agents;Surgical Pathology Clinics;2023-09

5. Marginal zone lymphoma: 2023 update on diagnosis and management;American Journal of Hematology;2023-08-21